AZ, “We do not consider withdrawing Tagrisso from getting health insurance benefits”

While patient associations are pressing the National Health Insurance Service(NHIS) and AstraZeneca to conclude the drug price negotiation for the company’s non-small cell lung cancer treatment, Tagrisso(generic name: osimertinib), AstraZeneca also said they would do the best for the negotiation and was not considering to withdraw from getting the insurance benefits.

Patient association, such ...